Press Releases

PRESS RELEASE

Jerini AG LISTED BY TORNADO INSIDER AS ONE OF EUROPE'S TOP 100 START-UPS

BERLIN, Germany (August 26, 2002) - Jerini AG was recently named in the second annual 'Tornado Insider 100' list as one of Europe's top most promising and innovative emerging private tech companies. Jerini, headquartered in Berlin, was founded in 1994 by Prof. Jens Schneider-Mergener and specializes in peptide-originated drug discovery and development.

"We are very pleased that our drug discovery strategy "From Peptides to Drugs" has been recognized by Tornado Insider," said Prof. Schneider-Mergener, CEO of Jerini AG. "We have a strong team who has developed great technologies and products and we are proud to be recognized and one of the Tornado Insider Top 100 start-ups in Europe."

The list, which is detailed in the summer issue of Tornado Insider magazine and on their website (www.tornado-insider.com) due in July, profiles Jerini and the other 99 most promising and innovative emerging companies in the European IT and biotech sectors.

"These companies are the elite of Europe," said Timothy Weeks, Tornado Insider's Senior Research Analyst. "They have clearly demonstrated that the technology they are commercializing today will change the way things are done tomorrow."

The selection of Jerini and the rest of the top 100 was narrowed from thousands of candidates and judged by the following criteria: 

Delivering an innovation that shows the promise of setting new standards.

Introducing a major new audience.

Supplying a key piece of the ICT infrastructure.

Commanding a significant customer base.

Having the potential to become a global brand or standard.

Influencing a major market.

Receiving a significant amount of funding.

Having a strong valuation for a future IPO.

The companies selected had to also meet the requirement of selling products that match their marketing promises as well as exhibit an ability of utilizing their funding in the most effective manner. Indicative of this years 'follow the money' philosophy, biotech and Israel were included in this year's list.

About Jerini AG
Jerini is a biopharmaceutical company which uses its technology platforms SPOT™, PepStar™ and PepMed™ to accelerate crucial steps in peptide-originated drug lead discovery and development. The company's unique core technology, its proprietary peptide/peptidomimetic array technology, enables the company to efficiently map protein-protein interactions, identify peptide lead compounds and systematically transform them into either peptidomimetics or small molecule drug candidates. Jerini recently launched peptide micro-array for applications in kinase- and protease-related drug discovery. Jerini has a staff of 85 and is supported by international (TVM, 3i, Polytechnos, Sanders Morris and Harris) as well as domestic investors (IBB, bmp and tbg).

For further information contact:

Jerini AG:
Invalidenstr. 130
10115 Berlin
Germany
T +49-30-9 78 93-0
F +49-30-9 78 93-105

2851 characters/ 433 words

<<Back